Israel’s Teva has been granted fast-track status for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody developed for the preventive treatment of migraine. It also applies to the prevention of cluster headaches, which are similar to migraines in symptoms.
Fast-track for migraine treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.